UNSPSC 51392415: Dopexamine hydrochloride

This classification denotes a dopamine agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VN909S60Y. European Medicines Agency schedules Dopexamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01819MIG. Dopexamine hydrochloride generally arises in the molecular formula C22H32N2O2.2CLH. The term 'dopexamine hydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule dopexamine hydrochloride under HS 29222900 and SITC 51462.

As of Q4 2014, DOPEXAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dopexamine hydrochloride bears US NLM identifiers UMLS ID C0770936 and NCI Concept Code C76650. SMILES: C1CCC(CC1)CCNCCCCCCNCCC2CCC(C(C2)O)O.CL.CL.

UNSPSC 51392415 Dopexamine hydrochloride, a Commodity code, nominally describes a specific pharmaceutical agent, but recent state and local solicitations tagged to this code show minimal direct relevance to dopexamine procurement. The Seminole County, Florida IFB60459723LAS solicitation (posted Jun 30, 2026, response due Jul 26, 2023) seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, which are opioid-reversal and harm-reduction products unrelated to dopexamine. The Texas Health and Human Services Commission RFI HHS0017013 (posted Apr 3, 2026) solicits vendor capabilities for a Direct-to-Manufacturer Prescriptions program under its Therapeutic Pharmacy Initiative, gathering market intelligence on direct contracting arrangements between state pharmacy benefit programs and manufacturers — a procurement mechanism and service model rather than a specific pharmaceutical commodity. The code shows little activity aligned with dopexamine procurement itself; instead, the tagged opportunities reflect broader pharmaceutical procurement, drug harm-reduction initiatives, and state-level pharmacy benefit program infrastructure.

Issuing bodies soliciting under this code include a county health department (Seminole County) procuring opioid-reversal supplies and a state health agency (Texas HHS Commission) conducting exploratory procurement for pharmacy benefit management services. Geographic activity centers on Florida and Texas. The Seminole County procurement is structured as a competitive IFB with quarterly deliveries, a two-year initial term plus one-year renewal option, and standard compliance requirements including E-Verify and workers' compensation insurance; the contract is potentially FEMA-funded. The Texas RFI represents a preliminary market-intelligence phase with no formal timeline, evaluation criteria, or budget allocation specified, designed to inform subsequent RFP development. Neither solicitation targets dopexamine hydrochloride specifically, signaling that vendors pursuing this code should verify alignment with actual pharmaceutical product categories in use by target customers rather than relying on the nominal code name alone.